# Intrusion Inc: financial statements, quarterly

INTZ · Nasdaq · CIK 736012 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/intz.md) · [Financials](/companies/intz/financials.md) · [Filings](/companies/intz/filings.md) · [Insiders](/companies/intz/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/intz/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [1,468](/filings/0001683168-24-007926.md) | [1,366 d](/filings/0001683168-25-001272.md) | [1,131](/filings/0001683168-25-002943.md) | [1,460](/filings/0001683168-25-005985.md) | [1,504](/filings/0001683168-25-008171.md) | [1,676 d](/filings/0001683168-26-002196.md) | [1,775](/filings/0001683168-26-003931.md) | [1,873](/filings/0001683168-26-006209.md) | [1,966](/filings/0001683168-25-008171.md) | [1,401 d](/filings/0001683168-26-002196.md) | [888](/filings/0001683168-26-003931.md) | [1,453](/filings/0001683168-26-006209.md) |
| Cost of revenue | $k | [324](/filings/0001683168-24-007926.md) | [290 d](/filings/0001683168-25-001272.md) | [226](/filings/0001683168-25-002943.md) | [350](/filings/0001683168-25-005985.md) | [344](/filings/0001683168-25-008171.md) | [421 d](/filings/0001683168-26-002196.md) | [432](/filings/0001683168-26-003931.md) | [442](/filings/0001683168-26-006209.md) | [461](/filings/0001683168-25-008171.md) | [380 d](/filings/0001683168-26-002196.md) | [229](/filings/0001683168-26-003931.md) | [488](/filings/0001683168-26-006209.md) |
| Gross profit | $k | [1,144](/filings/0001683168-24-007926.md) | [1,076 d](/filings/0001683168-25-001272.md) | [905](/filings/0001683168-25-002943.md) | [1,110](/filings/0001683168-25-005985.md) | [1,160](/filings/0001683168-25-008171.md) | [1,255 d](/filings/0001683168-26-002196.md) | [1,343](/filings/0001683168-26-003931.md) | [1,431](/filings/0001683168-26-006209.md) | [1,505](/filings/0001683168-25-008171.md) | [1,101 d](/filings/0001683168-26-002196.md) | [659](/filings/0001683168-26-003931.md) | [965](/filings/0001683168-26-006209.md) |
| Research and development | $k | [1,171](/filings/0001683168-24-007926.md) | [1,138 d](/filings/0001683168-25-001272.md) | [1,019](/filings/0001683168-25-002943.md) | [1,035](/filings/0001683168-25-005985.md) | [1,150](/filings/0001683168-25-008171.md) | [1,231 d](/filings/0001683168-26-002196.md) | [1,218](/filings/0001683168-26-003931.md) | [1,332](/filings/0001683168-26-006209.md) | [1,329](/filings/0001683168-25-008171.md) | [1,293 d](/filings/0001683168-26-002196.md) | [1,451](/filings/0001683168-26-003931.md) | [1,145](/filings/0001683168-26-006209.md) |
| Operating income | $k | [(2,693)](/filings/0001683168-24-007926.md) | [(2,388) d](/filings/0001683168-25-001272.md) | [(2,472)](/filings/0001683168-25-002943.md) | [(2,033)](/filings/0001683168-25-005985.md) | [(2,038)](/filings/0001683168-25-008171.md) | [(1,903) d](/filings/0001683168-26-002196.md) | [(2,093)](/filings/0001683168-26-003931.md) | [(2,086)](/filings/0001683168-26-006209.md) | [(2,136)](/filings/0001683168-25-008171.md) | [(2,849) d](/filings/0001683168-26-002196.md) | [(3,572)](/filings/0001683168-26-003931.md) | [(2,493)](/filings/0001683168-26-006209.md) |
| Interest expense | $k | [520](/filings/0001683168-23-008126.md) | [429 d](/filings/0001683168-24-002011.md) | [228](/filings/0001683168-24-003495.md) | [34.0](/filings/0001683168-24-005587.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(3,211)](/filings/0001683168-24-007926.md) | [(2,817) d](/filings/0001683168-25-001272.md) | [(1,716)](/filings/0001683168-25-008171.md) | [(2,067)](/filings/0001683168-25-008171.md) | [(2,050)](/filings/0001683168-25-008171.md) | [(1,957) d](/filings/0001683168-26-002196.md) | [(2,098)](/filings/0001683168-26-003931.md) | [(2,042)](/filings/0001683168-26-006209.md) | [(2,094)](/filings/0001683168-25-008171.md) | [(2,825) d](/filings/0001683168-26-002196.md) | [(3,563)](/filings/0001683168-26-003931.md) | [(2,590)](/filings/0001683168-26-006209.md) |
| Diluted EPS | $ per share | [(2.78)](/filings/0001683168-24-007926.md) | not reported | [(0.94)](/filings/0001683168-25-002943.md) | [(0.53)](/filings/0001683168-25-005985.md) | [(0.35)](/filings/0001683168-25-008171.md) | not reported | [(0.11)](/filings/0001683168-26-003931.md) | [(0.10)](/filings/0001683168-26-006209.md) | [(0.10)](/filings/0001683168-25-008171.md) | not reported | [(0.18)](/filings/0001683168-26-003931.md) | [(0.13)](/filings/0001683168-26-006209.md) |
| Basic EPS | $ per share | [(2.78)](/filings/0001683168-24-007926.md) | not reported | [(0.94)](/filings/0001683168-25-002943.md) | [(0.53)](/filings/0001683168-25-005985.md) | [(0.35)](/filings/0001683168-25-008171.md) | not reported | [(0.11)](/filings/0001683168-26-003931.md) | [(0.10)](/filings/0001683168-26-006209.md) | [(0.10)](/filings/0001683168-25-008171.md) | not reported | [(0.18)](/filings/0001683168-26-003931.md) | [(0.13)](/filings/0001683168-26-006209.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.2](/filings/0001683168-23-008126.md) | [0.1](/filings/0001683168-25-001272.md) | [0.1](/filings/0001683168-24-003495.md) | [1.5](/filings/0001683168-24-005587.md) | [1.1](/filings/0001683168-24-007926.md) | [4.9](/filings/0001683168-26-002196.md) | [10.7](/filings/0001683168-25-002943.md) | [4.7](/filings/0001683168-25-005985.md) | [2.5](/filings/0001683168-25-008171.md) | [3.6](/filings/0001683168-26-006209.md) | [1.4](/filings/0001683168-26-003931.md) | [0.2](/filings/0001683168-26-006209.md) |
| Current assets | $m | [0.9](/filings/0001683168-23-008126.md) | [1.1](/filings/0001683168-25-001272.md) | [0.8](/filings/0001683168-24-003495.md) | [2.6](/filings/0001683168-24-005587.md) | [2.5](/filings/0001683168-24-007926.md) | [5.5](/filings/0001683168-26-002196.md) | [12.1](/filings/0001683168-25-002943.md) | [10.5](/filings/0001683168-25-005985.md) | [7.6](/filings/0001683168-25-008171.md) | [4.2](/filings/0001683168-26-006209.md) | [2.0](/filings/0001683168-26-003931.md) | [2.3](/filings/0001683168-26-006209.md) |
| Total assets | $m | [4.7](/filings/0001683168-23-008126.md) | [6.2](/filings/0001683168-25-001272.md) | [5.7](/filings/0001683168-24-003495.md) | [7.5](/filings/0001683168-24-005587.md) | [7.4](/filings/0001683168-24-007926.md) | [11.5](/filings/0001683168-26-002196.md) | [18.0](/filings/0001683168-25-002943.md) | [16.4](/filings/0001683168-25-005985.md) | [13.7](/filings/0001683168-25-008171.md) | [10.4](/filings/0001683168-26-006209.md) | [7.9](/filings/0001683168-26-003931.md) | [12.5](/filings/0001683168-26-006209.md) |
| Current liabilities | $m | [15.7](/filings/0001683168-23-008126.md) | [14.3](/filings/0001683168-25-001272.md) | [5.4](/filings/0001683168-24-003495.md) | [3.1](/filings/0001683168-24-005587.md) | [3.5](/filings/0001683168-24-007926.md) | [3.7](/filings/0001683168-26-002196.md) | [3.0](/filings/0001683168-25-002943.md) | [3.2](/filings/0001683168-25-005985.md) | [2.4](/filings/0001683168-25-008171.md) | [1.8](/filings/0001683168-26-006209.md) | [2.9](/filings/0001683168-26-003931.md) | [6.0](/filings/0001683168-26-006209.md) |
| Shareholders' equity | $m | [11.5](/filings/0001683168-24-007926.md) | [(9.6)](/filings/0001683168-26-002196.md) | [(1.2)](/filings/0001683168-25-008171.md) | [2.9](/filings/0001683168-25-008171.md) | [2.6](/filings/0001683168-25-008171.md) | [6.3](/filings/0001683168-26-003931.md) | [13.4](/filings/0001683168-26-003931.md) | [11.6](/filings/0001683168-25-008171.md) | [9.8](/filings/0001683168-25-008171.md) | [7.3](/filings/0001683168-26-003931.md) | [3.7](/filings/0001683168-26-003931.md) | [4.1](/filings/0001683168-26-006209.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,504) d](/filings/0001683168-24-007926.md) | [(2,988) d](/filings/0001683168-25-001272.md) | [(1,114)](/filings/0001683168-25-002943.md) | [(2,922) d](/filings/0001683168-25-005985.md) | [(2,079) d](/filings/0001683168-25-008171.md) | [(178) d](/filings/0001683168-26-002196.md) | [(1,690)](/filings/0001683168-26-003931.md) | [(1,560) d](/filings/0001683168-26-006209.md) | [(2,978) d](/filings/0001683168-25-008171.md) | [(531) d](/filings/0001683168-26-002196.md) | [(1,821)](/filings/0001683168-26-003931.md) | [(3,590) d](/filings/0001683168-26-006209.md) |
| Capital expenditure | $k | [3.0 d](/filings/0001683168-24-007926.md) | [129 d](/filings/0001683168-25-001272.md) | [64.0](/filings/0001683168-25-002943.md) | [(31.0) d](/filings/0001683168-25-005985.md) | [33.0 d](/filings/0001683168-25-008171.md) | [467 d](/filings/0001683168-26-002196.md) | [392](/filings/0001683168-26-003931.md) | [333 d](/filings/0001683168-26-006209.md) | [34.0 d](/filings/0001683168-25-008171.md) | [18.0 d](/filings/0001683168-26-002196.md) | [54.0](/filings/0001683168-26-003931.md) | [1.0 d](/filings/0001683168-26-006209.md) |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [19.8](/filings/0001683168-23-008126.md) | [1.1](/filings/0001683168-24-003495.md) | [0.0](/filings/0001683168-24-005587.md) | [0.0](/filings/0001683168-24-007926.md) | [1.9](/filings/0001683168-25-002943.md) | [4.3](/filings/0001683168-25-005985.md) | [6.6](/filings/0001683168-25-008171.md) | [19.2](/filings/0001683168-26-003931.md) | [19.9](/filings/0001683168-26-006209.md) | [20.0](/filings/0001683168-25-008171.md) | [20.3](/filings/0001683168-26-003931.md) | [20.4](/filings/0001683168-26-006209.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 24,506,953 at 2026-08-11, from the cover of the [10-Q filed 2026-08-11](/filings/0001683168-26-006209.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.